The Food and Drug Administration has approved expanded use for Aciphex (rabeprazole sodium), a protonpump inhibitor, as a treatment for daytime and nighttime heartburn and other symptoms associated with gastro-esophageal reflux disease. Aciphex was discovered and developed by Eisai Co. and is co-marketed in the United States by Eisai and Janssen Pharmaceutica. An estimated 60 million Americans experience heartburn, the most common manifestation of symptomatic GERD, on a monthly basis.
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group
Home
A
8-Hour Bayer
